Welcome to the Cipla Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a prominent ...

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla" today announced a significant expansion of ...

SEBI-registered analyst Dhruv Tuli of Ascend Wealth noted Cipla’s strong technical breakout backed by momentum and volume, ...

Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The company expects continued growth from respiratory product launches and emerging ...

Cipla , India's third-largest drugmaker by sales, reported a better-than-expected quarterly profit on Friday, driven by higher domestic demand for its generic respiratory drugs.

Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the current Good ...

CIPLA Ltd. Annual stock financials by MarketWatch. View the latest CIPLA financial statements, income statements and financial ratios.

India's Cipla (CIPL.NS) said on Saturday that its manufacturing of the COVID-19 remdesivir drug was beginning to catch up with demand after the company sought to boost production amid a massive ...

The sale of a stake in Cipla Ltd. is in jeopardy as potential buyers have balked at the 1.09 trillion rupee ($13.1 billion) valuation members of the founding family are targeting for the Indian ...

Cipla--one of India's largest generic-drug manufacturers--said it is cutting prices for three cancer medicines it sells in India by up to 63%.